ArticleMolecular biology reports2026
Epigenomic dysregulation in the bone marrow mesenchymal stem cells of acquired aplastic anemia patients: An in silico and in vitro study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAplastic anemia (AA) is an immune-mediated bone marrow failure syndrome marked by pancytopenia and a hypocellular, fatty bone marrow. Growing evidence indicates that intrinsic abnormalities in bone marrow-derived mesenchymal stem cells (BM-MSCs), including inadequate hematopoietic support, cellular senescence, chronic inflammation, and enhanced adipogenic differentiation, contribute to disease pathophysiology. However, the epigenetic mechanisms underlying these abnormalities remain poorly understood. This work aims to define the epigenetic landscape of AA BM-MSCs and investigate key epigenetic regulators associated with niche failure. METHODS AND
resultsRNA sequencing data from AA patients and healthy controls were analyzed using bioinformatics methods, including differential gene expression analysis, Gene Ontology (GO) analysis, and Reactome pathway enrichment analysis. Principal component analysis revealed a clear separation between AA and control samples. Differential expression analysis identified 713 disrupted epigenetic regulators in AA BM-MSCs. Functional enrichment analysis indicated significant changes in pathways including chromatin remodelling, stem cell maintenance, DNA damage response, cellular senescence, inflammation, and lineage commitment. Quantitative real-time PCR validation confirmed overexpression of SETD1A, MLL1, EZH2, KDM3A, and PRMT1, and downregulation of DNMT3A, KDM2B, EHMT1, and KDM5C, consistent with the transcriptomic results.
conclusionsOur data show that AA BM-MSCs exhibit broad epigenetic dysregulation, which may contribute to bone marrow niche failure, chronic inflammation, senescence-associated changes, and reduced hematopoietic support. These findings provide novel insights into the epigenetic basis of AA pathobiology and suggest potential treatment targets to restore the function of the bone marrow microenvironment.
Indexed as
Identifiers
42429854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.